Selecta Biosciences, Inc. (NASDAQ:SELB) management will conduct a conference call for 5th November 2020 at 8:30 AM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website selectabio.com
Earnings Expectation
Selecta Biosciences, Inc. clinical-stage biopharmaceutical firm, is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.10 per share from revenue of $ 23.93 million. Looking ahead, the full year loss are expected at $ 0.42 per share on the revenues of $ 29.37 million.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The companys lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout.
